These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 14512224)

  • 1. An artificial solution for adoptive immunotherapy.
    Zemon H
    Trends Biotechnol; 2003 Oct; 21(10):418-20. PubMed ID: 14512224
    [No Abstract]   [Full Text] [Related]  

  • 2. [Dendritic cells--a new weapon in therapy of melanoma?].
    Enk A
    Hautarzt; 1996 Jun; 47(6):488-90. PubMed ID: 8778075
    [No Abstract]   [Full Text] [Related]  

  • 3. [Antitumor cellular immunotherapy: the breakthrough of dendritic cells].
    Angevin E; André F; Zitvogel L
    Bull Cancer; 2000 Jan; 87(1):107-15. PubMed ID: 10673639
    [No Abstract]   [Full Text] [Related]  

  • 4. Quality and quantity: new strategies to improve immunotherapy of cancer.
    Krueger C; Schneck JP; Oelke M
    Trends Mol Med; 2004 May; 10(5):205-8. PubMed ID: 15121045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of antigen-specific cytotoxic T lymphocytes using a leukemic plasmacytoid dendritic cell line as antigen presenting cells.
    Yamahira A; Narita M; Nakamura T; Watanabe N; Kaji M; Taniguchi T; Hashimoto S; Furukawa T; Toba K; Aizawa Y; Kuzushima K; Takahashi M
    Leuk Res; 2011 Jun; 35(6):793-9. PubMed ID: 21216464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cellular immunotherapy and glioblastoma: a hopeful treatment?].
    Larsen CJ
    Bull Cancer; 2011 May; 98(5):457. PubMed ID: 21796813
    [No Abstract]   [Full Text] [Related]  

  • 7. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of dendritic cells for the immunotherapy of tumors].
    Weise JB; Maune S; Kabelitz D; Heiser A
    HNO; 2005 Feb; 53(2):117-20. PubMed ID: 15657753
    [No Abstract]   [Full Text] [Related]  

  • 9. Decreased tumor surveillance after adoptive T-cell therapy.
    Matter M; Pavelic V; Pinschewer DD; Mumprecht S; Eschli B; Giroglou T; von Laer D; Ochsenbein AF
    Cancer Res; 2007 Aug; 67(15):7467-76. PubMed ID: 17671217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
    Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
    Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antigen-presenting cells in cellular immunotherapy].
    Narita M; Furukara T
    Rinsho Ketsueki; 2002 May; 43(5):368-73. PubMed ID: 12096489
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapy with dendritic cells for cancer.
    Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
    Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia.
    Dietz AB; Litzow MR; Gastineau DA; Vuk-Pavlović S
    Croat Med J; 2001 Aug; 42(4):428-35. PubMed ID: 11471194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current developments of immunotherapy in the clinic.
    Antonia S; Mulé JJ; Weber JS
    Curr Opin Immunol; 2004 Apr; 16(2):130-6. PubMed ID: 15023403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells and tumor immunity.
    Gunzer M; Jänich S; Varga G; Grabbe S
    Semin Immunol; 2001 Oct; 13(5):291-302. PubMed ID: 11502164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.
    Lin AM; Hershberg RM; Small EJ
    Urol Oncol; 2006; 24(5):434-41. PubMed ID: 16962496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells in cancer immunotherapy.
    Gunzer M; Grabbe S
    Crit Rev Immunol; 2001; 21(1-3):133-45. PubMed ID: 11642600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cellular immunotherapy for hematological malignancies].
    Yasukawa M
    Rinsho Ketsueki; 2008 Oct; 49(10):1460-71. PubMed ID: 18833930
    [No Abstract]   [Full Text] [Related]  

  • 19. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
    Bodey B; Siegel SE; Kaiser HE
    In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies.
    Hasan AN; Selvakumar A; Doubrovina E; Riviere I; Sadelain MW; O'Reilly RJ
    Discov Med; 2009 Dec; 8(43):210-8. PubMed ID: 20040272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.